Search Results (2)

Laurus azorica (Seub.) Franco is an endemic species from the Azores, traditionally used in all the islands as a seasoning in cooking. The studies carried out with this species refer mainly to its essential oils. The study that was developed here allowed, for the first time, to determine the chemical composition and biological activities of the ethanol extract, fractions, and pure compounds from L. azorica. The hexane fraction was analyzed by GC–MS and revealed the presence of 48 compounds, comprising mainly fatty acids, fatty alcohols and terpenes, the family of fatty alcohols identified here for the first time in the genus Laurus. Three sesquiterpene lactones—costunolide, 11,13-dehydrosantonin and reynosin—were isolated for the first time in L. azorica from the same fraction, and structurally characterized using spectroscopic techniques. The compounds identified belong to families known to have relevant medicinal and nutritional properties. Regarding antioxidant activities, the results obtained showed a moderate radical scavenging effect of extracts and fractions, while in the β-carotene bleaching assay, costunolide was shown to be the most active (IC₅₀ = 4.08 ± 0.76 μg/mL), about 3.6 times more active than the standard, gallic acid, which presented IC₅₀ = 14.56 ± 0.13 μg/mL. Although the inhibition of extracellular matrix-degrading enzymes was not detected, the ethanol extract showed good inhibitory activity of tyrosinase, with an IC₅₀ of 12.04 ± 0.23 μg/mL, only 6.6-fold lower than the control kojic acid. The results presented deepen the knowledge about a little studied species, opening new perspectives for the development of value-added applications in the food and cosmeceutical fields. Full article

Despite notable advances in utilising PARP inhibitor monotherapy, many cancers are not PARP inhibitor-sensitive or develop treatment resistance. In this work, we show that the two structurally-related sesquiterpene lactones, a 2-bromobenzyloxy derivative of dehydrosantonin (BdS) and alantolactone (ATL) sensitise p53 wildtype, homologous recombination-proficient cancer cells to low-dose treatment with the PARP inhibitor, olaparib. Exposure to combination treatments of olaparib with BdS or ATL induces cell-cycle changes, chromosomal instability, as well as considerable increases in nuclear area. Mechanistically, we uncover that mitotic errors likely depend on oxidative stress elicited by the electrophilic lactone warheads and olaparib-mediated PARP-trapping, culminating in replication stress. Combination treatments exhibit moderately synergistic effects on cell survival, probably attenuated by a p53-mediated, protective cell-cycle arrest in the G2 cell-cycle phase. Indeed, using a WEE1 inhibitor, AZD1775, to inhibit the G2/M cell-cycle checkpoint further decreased cell survival. Around half of all cancers diagnosed retain p53 functionality, and this proportion could be expected to increase with improved diagnostic approaches in the clinic. Utilising sublethal oxidative stress to sensitise p53 wildtype, homologous recombination-proficient cancer cells to low-dose PARP-trapping could therefore serve as the basis for future research into the treatment of cancers currently refractory to PARP inhibition. Full article